XM does not provide services to residents of the United States of America.
G
G

Galapagos


News

Kepler cuts Galapagos on 'Pyrrhic gamble' strategy

BUZZ-Kepler cuts Galapagos on 'Pyrrhic gamble' strategy ** Shares in Galapagos GLPG.AS drop around 3% after Kepler Cheuvreux cut the Dutch pharmaceutical company to "reduce" from "hold" ** The brokerage says Galapagos' high-risk strategy could ultimately result in a Pyrrhic victory - achieving outcomes at unreasonably high cost ** It points to regu
G

Imperial Brands, Morgan Sindall, WH Smith

EUROPE RESEARCH ROUNDUP-Imperial Brands, Morgan Sindall, WH Smith Nov 20 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Imperial Brands, Morgan Sindall and WH Smith on Wednesday. HIGHLIGHTS * Ashtead Group Plc AHT.L : Panmure Liberum raises PT to 6900p from 6333p * Genuit Group Plc GENG.L : RBC cuts target price to 505p from 515p * Imperial Brands IMB.L : RBC raises target price to 2,100p from 2,000p * Morgan Sindall MGNS.L : Panmu
A
A
A
A
B
C
C
D
E
G
G
H
H
I
N
P
P
S
S
T
V
W
B
E
I
U

Compass Group, Pandora, SSP Group

EUROPE RESEARCH ROUNDUP-Compass Group, Pandora, SSP Group Nov 7 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Compass Group, Pandora and SSP Group, on Thursday. HIGHLIGHTS * Compass Group CPG.L : Jefferies raises target price to 3,000p from 2,500p * Just Eat Takeaway.Com JETJ.L : JP Morgan raises target price to 1,415p from 1,396p * Marks and Spencer Group MKS.L : JP Morgan raises target price to 440p from 425p * Pandora PNDORA.C
A
B
C
C
E
F
F
G
G
I
K
M
P
P
S
S
S
S
S
Z
A

Galapagos NV reports results for the quarter ended in September 30 - Earnings Summary

Galapagos NV reports results for the quarter ended in September 30 - Earnings Summary Galapagos NV GLPG.AS reported a quarterly adjusted loss of 77 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of 39 cents. The mean expectation of two analysts for the quarter was for a loss of 49 cents per share.
G

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch Oct 30 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. VIVENDI VIV.PA : Paris-based investment fund CIAM said on Tuesday it would appeal to France's financial watchdog AMF to ensure shareholder rights are respected in Vivendi's plan to split up, urging a public offer be launched for Vivendi shares.
E
G
V
F
N
U

Galapagos NV <GLPG.OQ> expected to post a loss of 27 cents a share - Earnings Preview

Galapagos NV expected to post a loss of 27 cents a share - Earnings Preview Galapagos NV GLPG.OQ , GLPG.O is expected to show a fall in quarterly revenue when it reports results on October 30 for the period ending January 1 0001 The Malines (mechelen) Antwerpen-based company is expected to report a 41.8% decrease in revenue to $69.796 million from $120.03 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
G

Basler AG, Greatland Gold, Sandvik AB

EUROPE RESEARCH ROUNDUP-Basler AG, Greatland Gold, Sandvik AB Oct 22 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Basler AG, Greatland Gold and Sandvik AB, on Tuesday. HIGHLIGHTS * Autoneum Holding AG AUTON.S : UBS raises PT to CHF 170 from CHF 160 * Azelis NV AZE.BR : HSBC raises to buy from hold * Basler AG BSLG.DE : Jefferies cuts to hold from buy * Greatland Gold Plc GGPL.L : Berenberg cuts to hold from buy * Sandvik AB SAND
A
B
E
F
G
I
I
N
P
R
S
S
S
T
R

U.S. Galapagos, Marsh & Mclennan, Travelers

U.S. RESEARCH ROUNDUP-Galapagos, Marsh & Mclennan, Travelers Oct 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Galapagos, Marsh & Mclennan and Travelers, on Tuesday. HIGHLIGHTS * Contineum Therapeutics Inc CTNM.O : Baird initiates coverage with outperform rating * Galapagos NV GLPG.O : JP Morgan cuts target price to $32 from $37 * Marsh & Mclennan MMC.N : KBW raises target price to $212 from $209 * Travelers TRV.
A
C
E
E
G
M
T
W
Z
A
F
T
L
P
U
W
P
S

Galapagos jumps after appointing EcoR1's Nodelman to its board

BUZZ-Galapagos jumps after appointing EcoR1's Nodelman to its board ** Shares in pharmaceutical company Galapagos GLPG.AS rise 4.3% after it appoints Oleg Nodelman, founder and portfolio manager of EcoR1 Capital, to its board of directors ** EcoR1 in August reported a 9.9% stake in Galapagos and said it planned to communicate with the management and the board about topics relating to co's performance and board composition ** "(Nodelman) will bring his track record in business development and cap
G

Galapagos Receives Transparency Notification From Ecor1 Capital

BRIEF-Galapagos Receives Transparency Notification From Ecor1 Capital Sept 16 (Reuters) - Galapagos NV GLPG.AS : GALAPAGOS RECEIVES TRANSPARENCY NOTIFICATION FROM ECOR1 CAPITAL Source text for Eikon: ID:nGNX1Q9lfM Further company coverage: GLPG.AS ( Reuters.Briefs@thomsonreuters.com )
G

Ecor1 Capital Reports 9.9% Stake In Galapagos NV As Of Aug 19

BRIEF-Ecor1 Capital Reports 9.9% Stake In Galapagos NV As Of Aug 19 Aug 23 (Reuters) - Galapagos NV GLPG.AS : ECOR1 CAPITAL LLC REPORTS 9.9% STAKE IN GALAPAGOS NV AS OF AUG 19 - SEC FILING ECOR1 CAPITAL LLC SAYS BELIEVES GALAPAGOS NV'S SECURITIES ARE DEEPLY "UNDERVALUED" ECOR1 CAPITAL LLC - INTENDS TO COMMUNICATE WITH GALAPAGOS’ MANAGEMENT, BOARD
G

U.S. STOCKS Workday, Roku, Dexcom

BUZZ-U.S. STOCKS ON THE MOVE-Workday, Roku, Dexcom Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's stock indexes jumped on Friday, with the benchmark S&P 500 index nearing a record high, after U.S. Federal Reserve Chair Jerome Powell said "the time has come" to reduce interest rates.
G
I
Q
L
R
U
U

U.S. STOCKS Workday, CAVA Group, Roku

BUZZ-U.S. STOCKS ON THE MOVE-Workday, CAVA Group, Roku Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were set to open higher on Friday ahead of a speech from Federal Reserve Chair Jerome Powell that investors expect will offer hints on the pace of rate cuts in the world's biggest economy.
G
Q
R
U
E

U.S. STOCKS Workday, CAVA Group, Roku

BUZZ-U.S. STOCKS ON THE MOVE-Workday, CAVA Group, Roku Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures rose on Friday with investors awaiting Federal Reserve Chair Jerome Powell's comments at the Jackson Hole Economic Symposium for clues on interest-rate cuts in the world's biggest economy.
G
R
U
E

Galapagos rises on FDA clearance for phase 1/2 1 study

BUZZ-Galapagos rises on FDA clearance for phase 1/2 ATALANTA-1 study ** Shares in Galapagos GLPG.AS rise 2.7%, paring earlier gains of as much as 4%, after the Belgian biotech company obtained FDA clearance to initiate its ATALANTA-1 study with GLPG5101 in the U.S. ** "We see the FDA clearance as an important milestone for Galapagos' GLPG5101 program," says KBC Securities, adding the company will now be able to start treating patients in the U.S.
G
K

Galapagos: FDA Clears IND Application For Phase 1/2 1 Study

BRIEF-Galapagos: FDA Clears IND Application For Phase 1/2 ATALANTA-1 Study Aug 23 (Reuters) - Galapagos NV GLPG.AS : GALAPAGOS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR PHASE 1/2 ATALANTA-1 STUDY OF CD19 CAR-T, GLPG5101, IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA Source text for Eikon: ID:nGNX1gGlDF Further company coverage: GLPG.AS (Gdansk N
G



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.